Browsing Tag
Galmed Pharmaceuticals
2 posts
Can Galmed Pharmaceuticals avoid delisting? Nasdaq compliance clock is ticking
Nasdaq has notified Galmed Pharmaceuticals of a share price deficiency. Find out what this means for investors and the company's future strategy.
Galmed Pharmaceuticals (Nasdaq: GLMD) reports Q3 loss but refocuses on oncology with new Aramchol data and once-daily formulation
Galmed Pharmaceuticals shifts focus to oncology after reporting Q3 loss; Aramchol Meglumine’s new formulation shows promise for 2026 Phase 2 trials.